Artal Group S.A. Glycomimetics Inc Transaction History
Artal Group S.A.
- $1.58 Billion
- Q2 2024
A detailed history of Artal Group S.A. transactions in Glycomimetics Inc stock. As of the latest transaction made, Artal Group S.A. holds 8,589,064 shares of GLYC stock, worth $3.61 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
8,589,064
Previous 8,589,064
-0.0%
Holding current value
$3.61 Million
Previous $25.8 Million
90.67%
% of portfolio
0.15%
Previous 1.39%
Shares
6 transactions
Others Institutions Holding GLYC
# of Institutions
44Shares Held
25.7MCall Options Held
1.94MPut Options Held
153K-
Bvf Inc San Francisco, CA9.54MShares$4.01 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.7MShares$1.13 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny827KShares$347,2770.0% of portfolio
-
Goldman Sachs Group Inc New York, NY804KShares$337,8230.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$303,7370.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $22M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...